To join this case, fill out the form below
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Fusion Pharmaceuticals Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Fusion Pharmaceuticals Inc. (“Fusion” or the “Company”) (NASDAQ: FUSN) in connection with its proposed acquisition by a subsidiary of AstraZeneca.  Under the merger agreement, the Company’s shareholders will receive $21.00 per share at closing plus a non-transferable contingent value right (“CVR”) of $3.00 per share payable upon the achievement of a specified regulatory milestone.

Weiss Law is investigating whether (i) the Fusion board acted in the best interests of Company shareholders in agreeing to the merger, (ii) the merger consideration adequately compensates Fusion shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, at least one analyst set a price target for the Company of $24 per share.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

Other Cases